All About Multiple Sclerosis

More MS news articles for June 2003

Interferon beta promotes survival in primary astrocytes through phosphatidylinositol 3-kinase

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12799034&dopt=Abstract

J Neuroimmunol. 2003 Jun;139(1-2):155-159
Barca O, Ferre S, Seoane M, Prieto JM, Lema M, Senari;s R, Arce VM.
Departamento de Fisioloxi;a, Facultade de Medicina. Universidade de Santiago de Compostela, 15705, Santiago de Compostela, Spain

Although interferon-beta (IFN-beta) has been demonstrated to be effective in the treatment of multiple sclerosis (MS) patients, the mechanism(s) underlying its beneficial effects has not been uncovered yet.

Until now, most of the effort in the study of the relevant mechanisms of IFN-beta has dealt with its ability to modulate the immune response.

Only recently, it has been proposed that the beneficial effects of IFN-beta in MS patients could depend on its ability to modulate astrocyte function.

In the present work, we have found that IFN-beta treatment promotes the survival of astrocytes through stimulation of the phosphatidylinositol 3-kinase (PI-3K)/Akt pathway.

We propose that the beneficial effects of IFN-beta in MS therapy may depend, at least in part, on its capacity to protect astrocytes against the apoptotic cell death that occurs in the early steps of the pathogenesis of MS.